FOXA1 mutations were found in 3/8 (38%) lymph node metastases and in 1/23 (4%) CRPC metastases, whereas SPOP mutations were detected in 1/8 (13%) lymph node metastases and in 2/23 (9%) CRPC metastases (Fig. 1). Here, SPOP is linked to metastatic malignant neoplasm in the lymph nodes.